These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 24874727)
21. The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells. Garufi A; Ubertini V; Mancini F; D'Orazi V; Baldari S; Moretti F; Bossi G; D'Orazi G J Exp Clin Cancer Res; 2015 Aug; 34(1):87. PubMed ID: 26297485 [TBL] [Abstract][Full Text] [Related]
22. Radiation induces autophagic cell death via the p53/DRAM signaling pathway in breast cancer cells. Cui L; Song Z; Liang B; Jia L; Ma S; Liu X Oncol Rep; 2016 Jun; 35(6):3639-47. PubMed ID: 27109777 [TBL] [Abstract][Full Text] [Related]
23. Turmeric toxicity in A431 epidermoid cancer cells associates with autophagy degradation of anti-apoptotic and anti-autophagic p53 mutant. Thongrakard V; Titone R; Follo C; Morani F; Suksamrarn A; Tencomnao T; Isidoro C Phytother Res; 2014 Dec; 28(12):1761-9. PubMed ID: 25044209 [TBL] [Abstract][Full Text] [Related]
25. Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. Ubertini V; Norelli G; D'Arcangelo D; Gurtner A; Cesareo E; Baldari S; Gentileschi MP; Piaggio G; Nisticò P; Soddu S; Facchiano A; Bossi G Oncogene; 2015 May; 34(19):2493-504. PubMed ID: 24998848 [TBL] [Abstract][Full Text] [Related]
26. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Li D; Marchenko ND; Moll UM Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290 [TBL] [Abstract][Full Text] [Related]
27. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703 [TBL] [Abstract][Full Text] [Related]
28. APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner. Cun Y; Dai N; Li M; Xiong C; Zhang Q; Sui J; Qian C; Wang D Oncol Rep; 2014 Feb; 31(2):901-9. PubMed ID: 24297337 [TBL] [Abstract][Full Text] [Related]
29. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668 [TBL] [Abstract][Full Text] [Related]
30. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles. Zhang H; Zhang W; Hu B; Qin X; Yi T; Ye Y; Huang X; Song Y; Yang Z; Qian J; Zhang Y J Nanobiotechnology; 2023 Apr; 21(1):117. PubMed ID: 37005668 [TBL] [Abstract][Full Text] [Related]
31. Curcumin mediates selective aggregation of mutant p53 in cancer cells: A promising therapeutic strategy. Oak S; Karajgikar O; Teni T Biochem Biophys Res Commun; 2023 Oct; 677():141-148. PubMed ID: 37586212 [TBL] [Abstract][Full Text] [Related]
32. p53-Dependent PUMA to DRAM antagonistic interplay as a key molecular switch in cell-fate decision in normal/high glucose conditions. Garufi A; Pistritto G; Baldari S; Toietta G; Cirone M; D'Orazi G J Exp Clin Cancer Res; 2017 Sep; 36(1):126. PubMed ID: 28893313 [TBL] [Abstract][Full Text] [Related]
33. Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions. Cordani M; Garufi A; Benedetti R; Tafani M; Aventaggiato M; D'Orazi G; Cirone M Biomolecules; 2024 May; 14(6):. PubMed ID: 38927053 [TBL] [Abstract][Full Text] [Related]
34. Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation. Gillotin S; Yap D; Lu X Cell Cycle; 2010 Apr; 9(7):1390-8. PubMed ID: 20234175 [TBL] [Abstract][Full Text] [Related]
35. Butein inhibits cancer cell growth by rescuing the wild-type thermal stability of mutant p53. Song B; Wang J; Ren Y; Su Y; Geng X; Yang F; Wang H; Zhang J Biomed Pharmacother; 2023 Jul; 163():114773. PubMed ID: 37156116 [TBL] [Abstract][Full Text] [Related]
36. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma. Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964 [TBL] [Abstract][Full Text] [Related]
37. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. An WG; Chuman Y; Fojo T; Blagosklonny MV Exp Cell Res; 1998 Oct; 244(1):54-60. PubMed ID: 9770348 [TBL] [Abstract][Full Text] [Related]
38. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011 [TBL] [Abstract][Full Text] [Related]
39. JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. Sui X; Kong N; Wang X; Fang Y; Hu X; Xu Y; Chen W; Wang K; Li D; Jin W; Lou F; Zheng Y; Hu H; Gong L; Zhou X; Pan H; Han W Sci Rep; 2014 Apr; 4():4694. PubMed ID: 24733045 [TBL] [Abstract][Full Text] [Related]
40. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Göhler T; Jäger S; Warnecke G; Yasuda H; Kim E; Deppert W Nucleic Acids Res; 2005; 33(3):1087-100. PubMed ID: 15722483 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]